Discussion  by unknown
Complete surgical resection is the preferred treatment for
SFTPs. VATS was used in only 14% of our patients, but this
clearly reflects the 30-year time span of this series, with
VATS being available only in the latter 15 years. The
median SFTP size for VATS resections was 2.4 cm (range,
0.8–15 cm), and there were no recurrences. The median
SFTP size for open resections was 7 cm (range, 1–30 cm).
Pulmonary wedge excision was the most common surgical
procedure, occurring in nearly three quarters of our patients,
and formal anatomic lung parenchymal resections alone
were performed in only 6 (7.1%) patients. Chest wall resec-
tion alone was required in 3 (3.6%) patients and was associ-
ated with an additional lung parenchymal resection in 6
more patients. The operative approach and extent of surgical
excision should be dictated by the SFTP’s size and location.
SFTPs in our series ranged in size from 0.8 to 30 cm, with
a median diameter of 5 cm. Size was the best clinical predic-
tor of malignancy, with malignant tumors having a median
diameter of 12 cm in comparison with 4.5 cm in benign
tumors (P ¼ .001).
Long-term survival after resection of both benign and
malignant SFTPs is possible, with the overall median sur-
vival in our series being 24 years. However, long-term sur-
vival for completely resected benign SFTPs is dramatically
better than that of completely resected malignant SFTPs
(Figure 2). Long-term follow-up after complete resection
is necessary because SFTPs can recur, and this was seen
in 8 (9.9%) of our patients, including 2 patients with benign
histopathology. Several authors have not reported recur-
rence after complete resection of benign SFTPs.11,13,16,18,21
In contrast, reported recurrence rates for completely resected
malignant SFTPs range from 14% to 86%.11,13,16,18 In our
series there were 10 surviving operative patients with malig-
nant SFTPs, and 6 (75%) of these experienced recurrence.
In only 3 patients (2 with benign SFTPs and 1 with a malig-
nant SFTP) was the recurrence localized to the same hemi-
thorax. After reoperation, recurrence again occurred in 2
patients.
In conclusion, SFTPs are uncommon tumors that are best
treated with complete surgical resection. In this series
increased tumor size is suggestive of malignancy. Long-
term survival after resection of benign SFTPs is excellent
but is also possible after resection for malignant SFTPs.
However, malignant SFTPs are prone to recurrence, which
in turn is associated with a poor prognosis.
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Discussion
Dr Robert J. Downey (New York, NY). Karen, I enjoyed that
very much.
SFTPs are going to be seen by all of us, but sporadically, such
that it is for most surgeons to get a sense for the disease. Therefore
I enjoy articles like this that flesh out their behavior based on large
institutional experiences.
I have 2 comments and 3 questions. My first comment is that
when I went over the data, it was clear I thought this would be an
excellent opportunity with a large data set of pathologic material
to re-examine the pathologic criteria for malignancy. I think that
your data validate England and colleagues’ data from 1989, which
established criteria for separating benign from malignant tumors in
that those criteria accurately predicted those patients of yours who
were likely to have recurrence and those who were not.
My second comment is that you noted that fine-needle aspiration
(FNA) only yielded a diagnosis in about 45% of patients, and the
article suggests that you do not recommend performing FNA before
surgical intervention. I would suggest that your study is not de-
signed to address this question because you do not know the de-
nominator of the patients with solitary pulmonary nodules who
underwent needle biopsy. Diagnoses of other types of tumors might
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have been made in other patients. Your data simply suggest that if
you are eventually going to know that this tumor is a solitary fibrous
tumor, then you should not do a needle biopsy up front.
My questions are as follows. First, when these lesions are small,
operations are actually very easy. The large ones can be extremely
difficult, in that they can be hard to move around the chest, such that
you can have trouble finding the point of attachment, which is
clearly important for adequacy of resection. They can be hard to re-
move through an incision when they get up to 15 and 25 cm in size,
and they can be so large that they press against the boney structures
of the chest wall, develop venous engorgement, and bleed until the
chest is widely opened. You state only that these patients under-
went thoracotomies and sternotomies. Could you describe what ex-
tended approaches to the thorax, such as a hemiclamshell, you have
found useful in an attempt to achieve better exposure?
Second, some of the previous articles on benign fibrous tumors
have suggested that benign lesions can undergo malignant degener-
ation. Your data do not support this in that you saw only 1 patient
who had a recurrence that was read as malignant where the original
site of disease had been believed to be benign. To me, 1 transforma-
tion event in about 80 patients suggests that the problem is with the
adequacy of pathology, which in these other series might not have
been complete. These could be heterogeneous tumors, and if you
look carefully enough, you will eventually see the malignant
components.
Finally, based on the very poor outcomes seen in the patients
with malignant disease, are you recommending adjuvant therapy
once the resections have been completed?
Thank you.
Dr Harrison–Phipps. Thank you very much, Dr Downey, for
your comments and questions.
If I could just address one of your comments first, regarding the
FNA cytology, you correctly said that this had a positive predictive
value in 45% of our patients or that the sensitivity, rather, was cor-
rect in 45% of the patients, and this is pretty low. If you look
through a number of the series, the large series, in the majority of
them, it is really the minority of patients who have had a preopera-
tive FNA, but in no case series is the sensitivity higher than 45%,
and in some it is lower. I would say that there is 1 article that men-
tions that perhaps using a wide-bore, Tru-Cut biopsy needle might
result in improved diagnostic accuracy, but that was a small study
with only 5 patients. I think the problem that occurs is that it is dif-
ficult to decide whether they are benign or malignant solitary
fibrous tumors, and this is simply, as you said, because of the het-
erogeneity of the tumors. It would be easy to get an incorrect or
a sampling error.
Regarding the large tumors, in our series about a third of tumors
were larger than 15 cm, and in all our patients the resection was
complete. That is the first thing. When you look through the major-
ity of the case series, in fact, the majority of authors support the use
of a thoracotomy for resection of these tumors, and certainly there
are isolated case reports that describe a number of operative ap-
proaches for massive tumors, including hemiclamshell and so on.
We did use sternotomy in 3 patients, but, interestingly, those
were actually all for tumors of less than 10 cm, and it was just their
location and not the size that prompted the choice of this incision.
Therefore what I would say is that I truly advocate the use of the
hemiclamshell incision. I think it is an excellent incision with great
exposure. It is just that we did not find it necessary in our series.
Our largest tumor was 30 cm, and in all cases all tumors were
removed through an extended posterolateral thoracotomy, if
necessary.
Regarding the transformation from benign to malignant, there
was only 1 such patient in our series. We did go back and ask the
pathologists to review the slides, and they confirmed that in fact
the original pathology was benign and the recurrence was malig-
nant. Various case series report no changes. I think the problem
is that these tumors are such a mixed bag, it really depends what
you are going to get. In some series the incidence is higher. I just
really think they are very individual tumors.
Regarding your question on adjuvant or neoadjuvant therapies,
chemotherapy or radiotherapy, there really are no data to make
any legitimate comment. There are certainly isolated comments
within oncology articles, and one in particular mentioned a patient
who had positive resection margins with an almost inoperable tu-
mor, an unresectable tumor. This patient had radiotherapy that
shrunk the tumor and was alive 20 years later. That was a benign
tumor. In another case a patient received adriamycin and isophos-
phamide and experienced some tumor shrinkage. But really, there
are no real data to support the use or choice of any regimen at all.
Dr P. Michael McFadden (Los Angeles, Calif). Dr Harrison–
Phipps, I have one question for you. You mentioned a number of
different tumor types that historically have been brought up: benign
mesotheliomas, solitary fibrous tumors, and others. Mesotheliomas
and these fibrous tumors can easily be differentiated now by using
immunohistochemical techniques. I was wondering whether you
verified the difference between the malignant tumors that you re-
moved and the 1 benign tumor that turned into a malignant tumor
on second biopsy using immunohistochemical techniques.
Dr Harrison–Phipps. Thank you, Dr McFadden, for your com-
ment and your question.
The study goes back to 1972, and therefore the first thing I would
say is that not all these immunohistochemical techniques were
available then, but in the majority of patients, the pathology reports
did include immunocytochemistry, and the markers that were
looked at were vimentin, cytokeratin, CD34, CD99, and Bcl-2.
As you correctly point out, malignant mesothelioma is positive
for cytokeratin but negative for these mesenchymal markers. The
thing is that it does not necessarily help you with deciding which
are benign and which are malignant. The only thing I can tell
you is that there might be some future markers that could help pre-
dict recurrence, and one of these is called p16, which has been
showing early promise at predicting recurrence with these solitary
fibrous tumors.
Dr Michael Lanuti (Boston, Mass). I enjoyed your presenta-
tion.
One of the things that I and perhaps my colleagues struggle with
is how to follow these patients. I would like your comments. I think
that a malignant phenotype is a bit easier, and you would probably
image them more frequently. In contrast, how often were patients
with a benign phenotype screened during follow-up in your study?
I struggle with how often one should image these patients because
there is a small risk of malignant degeneration.
Dr Harrison–Phipps. Thank you very much for your question.
I think I would come back to the sensitivity of the imaging.
Amazingly, chest radiographic analysis showed a sensitivity of
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92%, and CT scanning showed a sensitivity of 98%. Therefore
what I would say is that for patients with malignant tumors, they
ought to be followed up for certain with a CT scan. I have some
data on the recurrences and when they recurred. Of the 6 patients
who experienced recurrence, the median time to recurrence was
37 months. Therefore you are predicting an early recurrence. The
range of that was quite significant. It was actually from 12 to 132
months. Therefore there was a wide range. I guess the bottom
line is that you have to be very vigilant at all times. It is very diffi-
cult to give you an exact answer, but I would certainly think that an
annual or at least a 6-month CT scan would be essential for patients
with malignant solitary fibrous tumors. I think it is easier for pa-
tients with benign tumors. You know, the risk of transformation
from a benign tumor to a malignant tumor is low, and personally,
I think an annual CT scan would be advisable. For people who
have health care economic issues, a chest radiographic scan is al-
most as good at 92% sensitivity, but I certainly think at least an an-
nual follow-up would be necessary for benign tumors and perhaps
a 6-month follow-up for malignant tumors.
Dr Jhingook Kim (Seoul, South Korea). We have reported
about 50 cases of our experience about 4 years ago. I have 3 ques-
tions or comments about how to approach these patients.
First of all, in my experience we do not have many patients who
require anatomic lung resection. This is the case for the SFTPs. In
most of the patients, we need just a wedge resection or otherwise
just to catch the tumor from the pleural cavity. In your report you
have so many pneumonectomies and lung resections.
Second, if the tumor is not so big, it is quite easy to just catch it.
However, if the tumor is fairly big, we can resect the tumor portion
by portion using small incisions. Because most of the fibrous tu-
mors are benign, there is no need to approach with such a big inci-
sion, including the hemiclamshell.
My third question is this: What do you think about the need for
neoadjuvant treatment if the tumor looks malignant or if the FNA
shows the malignancy?
Thank you for your attention.
Dr Harrison–Phipps. Thank you very much, Dr Kim.
With regard to your first question, in so many lung resections the
majority of the tumors are pedunculated, they arise from the vis-
ceral pleura, and they are on a stalk. I think the number of lung re-
sections was probably around 10 or less in total. The majority of our
excisions were wedge excisions. Seventy percent were wedge exci-
sions. Therefore I concur with what you say. But I would caution
you, because the bottom line is that you do not actually know the
pathology until you remove the specimen. One of our predecessors,
Dr Bernatz, has come up with a very useful comment, and he basi-
cally advises to consider the advice of the professional golfer to the
weekend golfer: do not underclub. Do not underestimate these tu-
mors. You have got to be careful. You want to take a little bit extra,
if you can.
With regard to your second question concerning no need for
large incisions for larger tumors, do I understand that you remove
these piecemeal? I was not quite sure what you were meaning there.
I understand you remove them bit by bit.
To come back to the first comment, I certainly think the postero-
lateral thoracotomy is very useful for large tumors. You really want
to get all the tumor out, if you can. You are aiming for a clear re-
section margin. This is what the large case series of 232 patients
by England and colleagues supported. You are quite right to sug-
gest that the majority are very easy operations, some even using
VATS. It is a polypoid tumor that is easy to remove. But we
have to be careful with the larger ones because there is a risk of re-
currence, even with benign tumors, and the larger the tumors, obvi-
ously they could be malignant, and I really think that it is important
to think about your operative approach. In most cases a posterolat-
eral thoracotomy would be fine, but perhaps there are arguments for
more extended operations as well.
As for the need for neoadjuvant treatment, I do not know
whether we will ever get to know this. First of all, the tumors are
very rare. A preoperative diagnosis is hard to establish, certainly
for malignant tumors. You would never get it on the basis of an in-
adequate or uncertain report, and it is really unusual for an FNA to
diagnose a malignant SFTP preoperatively. Therefore I am not
sure we will ever see many patients who have had neoadjuvant
treatment.
Dr Jean Deslauriers (Quebec City, Quebec, Canada). This is
an academic question really. These tumors classically are associ-
ated with paraneoplastic syndromes, such as clubbing and hypo-
glycemia. In fact, the classic presentation is that it is a big tumor
with clubbing. Maybe you mentioned it in your presentation, but
I did not hear it. What percentage of these patients really had
one or the other classic paraneoplastic syndromes, such as club-
bing, and does this have an effect on whether the tumor is be-
nign at the end of the day or malignant? Because this is one
of the largest, if not the largest, series of such tumors, I would
be interested to know the exact incidence of these paraneoplastic
syndromes, if you were able to look at that aspect of these
tumors.
Dr Harrison–Phipps. Thank you very much for your question,
Dr Deslauriers.
The incidence of hypertrophic pulmonary osteoarthropathy in
this series was 8 patients, or 9.9%; the incidence of persons with
clubbing was 3 patients; and the incidence of hypoglycemia was
1 patient. You quite rightly mentioned these names, and these
names have syndromes in the literature. Hypoglycemia is known
as the Doege–Potter syndrome and hypertrophic pulmonary osteo-
arthropathy, and clubbing is known as the Pierre–Marie–Bamberg
syndrome. In our series it was 10% for these symptoms. That is
pretty much what you can find in the other series as well. There
are 1 or 2 series with more or less, but really, in our series, of those
8 patients or 9 with hypoglycemia who had these symptoms, only 2
were malignant. Therefore I do not really think we can say it pre-
dicts malignancy. It is simply due to the fact that for osteoarthrop-
athy, they might have an excess production of hyaluronic acid, and
for hypoglycemia, they have an excess production of insulin 2
growth–like factor. It is difficult to say. I do not necessarily think
it is related to size or malignancy. It is just a very interesting feature
of these unusual tumors.
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